Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma von Abou-Alfa, Ghassan K, Meyer, Tim, Cheng, Ann-Lii, El-Khoueiry, Anthony B, Rimassa, Lorenza, Ryoo, Baek-Yeol, Cicin, Irfan, Merle, Philippe, Chen, YenHsun, Park, Joong-Won, Blanc, Jean-Frederic, Bolondi, Luigi, Klümpen, Heinz-Josef, Chan, Stephen L, Zagonel, Vittorina, Pressiani, Tiziana, Ryu, Min-Hee, Venook, Alan P, Hessel, Colin, Borgman-Hagey, Anne E, Schwab, Gisela, Kelley, Robin K

Volltext

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma von Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N, Rini, Brian I, Donskov, Frede, Hammers, Hans, Hutson, Thomas E, Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J, Bjarnason, Georg A, Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C, Schmidinger, Manuela, Kantoff, Philip W, Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M, Tannir, Nizar M, Motzer, Robert J

Volltext

A Phase I Trial and in vitro Studies Combining ABT-751 with Carboplatin in Previously Treated Non-Small Cell Lung Cancer Patients von Ma, Tian, Fuld, Alexander D., Rigas, James R., Hagey, Anne E., Gordon, Gary B., Dmitrovsky, Ethan, Dragnev, Konstantin H.

Volltext

A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors von Fox, Elizabeth, Maris, John M, Widemann, Brigitte C, Goodspeed, Wendy, Goodwin, Anne, Kromplewski, Marie, Fouts, Molly E, Medina, Diane, Cohn, Susan L, Krivoshik, Andrew, Hagey, Anne E, Adamson, Peter C, Balis, Frank M

Volltext

A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer von Mauer, Ann M., Cohen, Ezra E.W., Ma, Patrick C., Kozloff, Mark F., Schwartzberg, Lee, Coates, Andrew I., Qian, Jiang, Hagey, Anne E., Gordon, Gary B.

Volltext

The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study von HANDE, Kenneth R, HAGEY, Anne, ROTHENBERG, Mace L, BERLIN, Jordan, YINGNA CAI, MEEK, Kysa, KOBAYASHI, Hiro, LOCKHART, A. Craig, MEDINA, Diane, SOSMAN, Jeffrey, GORDON, Gary B

Volltext

Pharmacokinetics and Safety of Marqibo (Vincristine Sulfate Liposomes Injection) in Cancer Patients With Impaired Liver Function von Bedikian, Agop Y., Silverman, Jeffrey A., Papadopoulos, Nicholas E., Kim, Kevin B., Hagey, Anne E., Vardeleon, Anna, Hwu, Wen-Jen, Homsi, Jade, Davies, Michael, Hwu, Patrick

Volltext

A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors von Fox, Elizabeth, Maris, John M, Widemann, Brigitte C, Meek, Kysa, Goodwin, Anne, Goodspeed, Wendy, Kromplewski, Marie, Fouts, Molly E, Medina, Diane, Cho, Steve Y, Cohn, Susan L, Krivoshik, Andrew, Hagey, Anne E, Adamson, Peter C, Balis, Frank M

Volltext

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies von YEE, Karen W. L, HAGEY, Anne, FERRAJOLI, Alessandra, ALBITAR, Maher, MCKEEGAN, Evelyn, GRIMM, David R, MUELLER, Toby, HOLLEY-SHANKS, Rhonda R, SAHELIJO, Leonardo, GORDON, Gary B, KANTARJIMI, Hagop M, GILES, Francis J, VERSTOVSEK, Srdan, CORTES, Jorge, GARCIA-MANERO, Guillermo, O'BRIEN, Susan M, FADERL, Stefan, THOMAS, Deborah, WIERDA, William, KORNBLAU, Steven

Volltext

Cabozantinib in Hepatocellular Carcinoma von Maeda, Osamu, Ando, Yuichi, Abou-Alfa, Ghassan K, Borgman-Hagey, Anne E, Kelley, Robin K

Volltext

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL... von Abou-Alfa, Ghassan K., Meyer, Tim, Cheng, Ann-Lii, El-Khoueiry, Anthony, Rimassa, Lorenza, Ryoo, Baek-Yeol, Cicin, Irfan, Merle, Philippe, Chen, Yen-Hsun, Park, Joong-Won, Blanc, Jean-Frédéric, Bolondi, Luigi, Klümpen, Heinz Josef, Chan, Stephen Lam, Dadduzio, Vincenzo, Hessel, Colin, Borgman-Hagey, Anne E., Schwab, Gisela, Kelley, Robin Kate

Volltext

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIA... von Abou-Alfa, Ghassan K., Meyer, Tim, Cheng, Ann-Lii, El-Khoueiry, Anthony B., Rimassa, Lorenza, Ryoo, Baek-Yeol, Cicin, Irfan, Merle, Philippe, Park, Joong-Won, Blanc, Jean-Frédéric, Bolondi, Luigi, Klümpen, Heinz Josef, Chan, Stephen Lam, Dadduzio, Vincenzo, Hessel, Colin, Borgman-Hagey, Anne E., Schwab, Gisela, Kelley, Robin Kate

Volltext

Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NC... von Abou-Alfa, Ghassan K., Cheng, Ann-Lii, Meyer, Tim, El-Khoueiry, Anthony B., Ikeda, Masafumi, Chun, Hoo Geun, Furuse, Junji, Knox, Jennifer J., Okusaka, Takuji, Ping, Jerry, Borgman-Hagey, Anne E., Kelley, Robin Kate

Volltext

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma von Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N, Rini, Brian I, Donskov, Frede, Hammers, Hans, Hutson, Thomas E, Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J, Bjarnason, Georg A, Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C, Schmidinger, Manuela, Kantoff, Philip W, Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M, Tannir, Nizar M, Motzer, Robert J, METEOR Investigators

Volltext

Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NC... von Abou-Alfa, Ghassan K., Cheng, Ann-Lii, Meyer, Tim, El-Khoueiry, Anthony B., Ikeda, Masafumi, Chun, Hoo Geun, Faivre, Sandrine J., Furuse, Junji, Knox, Jennifer J., Okusaka, Takuji, Ping, Jerry, Borgman-Hagey, Anne E., Kelley, Robin Kate

Volltext

Peripheral Neuropathy Profile of Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®), a Nanoparticle Vincristine Formulation, in Adult Subjects with Relapsed/Refractory Acute... von Lu, Biao, Hagey, Anne E, Zhou, Feng, Deitcher, Steven R.

Volltext

A Recombinant Antibody to EphA3 for the Treatment of Hematologic Malignancies: Research Update and Interim Phase 1 Study Results von Hagey, Anne, Lancet, Jeffrey E., Palath, Varghese, Wei, Andrew H, Lackmann, Martin, Cortes, Jorge E., Boyd, Andrew, Shochat, Dan, Yarranton, Geoffrey, Bebbington, Christopher, Leff, Jonathan A.

Volltext

Marqibo® (vincristine sulfate liposomes injection; VSLI) In the Treatment of Adult Patients with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analys... von O'Brien, Susan, Thomas, Deborah A, Heffner, Leonard T, Stock, Wendy, Messerschmidt, Gerald L., Hagey, Anne, Deitcher, Steven R., Kantarjian, Hagop

Volltext

Increasing diversity in pediatric hematology/oncology von Frugé, Ernest, Lakoski, Joan M., Luban, Naomi, Lipton, Jeffrey M., Poplack, David G., Hagey, Anne, Felgenhauer, Judy, Hilden, Joanne, Margolin, Judith, Vaiselbuh, Sarah R., Sakamoto, Kathleen M.

Volltext

In Vivo Anti-Tumor Efficacy of Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Multiple Myeloma von Sanchez, Eric, Steinberg, Jeffrey A, Li, Mingjie, Chen, Haiming, Bonavida, Benjamin, Deitcher, Steven R., Hagey, Anne E, Berenson, James R.

Volltext